KDR and hepatocellular carcinoma: We previously revealed that lenvatinib targets VEGF‐ and FGF‐induced angiogenesis 7, 8, 11, and therefore the blocking of not only VEGFR but also FGFR by lenvatinib might be behind its potent anti‐angiogenic and antitumor activities in the HCC models.